6-methyl-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-1H-pyrazol[3,4-b]pyridine | 1075253-38-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 6-methyl-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-1H-pyrazol[3,4-b]pyridine
• 英文别名: 2-[1-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)pyrazol-3-yl]-1,3-thiazole
• CAS: 1075253-38-1
• 化学式: C₁₃H₁₀N₆S
• 分子量: 282.329
• InChiKey: XTBCRQLDGVKVGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-methyl-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-1H-pyrazol[3,4-b]pyridine 、 4-溴-3-甲基苯甲腈 在 copper(l) iodide 、 caesium carbonate 、 1,2-二氨基环己烷 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以8%的产率得到3-methyl-4-(6-methyl-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl)benzonitrile
  参考文献：
  名称：

  Dihydropyrrole[2,3-d]pyridine Derivatives as Novel Corticotropin-Releasing Factor-1 Antagonists: Mapping of the Receptor Binding Pocket by in Silico Docking Studies

  摘要：

  In an effort to discover novel CRF-1 receptor antagonists exhibiting improved physicochemical properties, a dihydropirrole[2,3]pyridine scaffold was designed and explored in terms of the SAR of the substitution at the pendent phenyl ring and the nature of the heterocyclic moieties present in the upper region of the molecule. Selective and potent compounds have been discovered endowed with reduced ClogP with respect to compounds known in the literature. Of particular relevance was the finding that the in vitro affinity of the series was maintained by reducing the overall lipophilicity. The results achieved by this exploration enabled the formulation of a novel hypothesis on the nature of the receptor binding pocket of this class of CRF-1 receptor antagonists, making use of in silico docking studies of the putative nonpeptidic antagonist binding site set up in house by homology modeling techniques.

  DOI：

  10.1021/jm800743q
• 作为产物：
  描述：

  2-chloro-6-methyl-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-3-pyridinecarbaldehyde 在 一水合肼 作用下， 以 乙醇 为溶剂， 以54%的产率得到6-methyl-4-[3-(1,3-thiazol-2-yl)-1H-pyrazol-1-yl]-1H-pyrazol[3,4-b]pyridine
  参考文献：
  名称：

  Dihydropyrrole[2,3-d]pyridine Derivatives as Novel Corticotropin-Releasing Factor-1 Antagonists: Mapping of the Receptor Binding Pocket by in Silico Docking Studies

  摘要：

  In an effort to discover novel CRF-1 receptor antagonists exhibiting improved physicochemical properties, a dihydropirrole[2,3]pyridine scaffold was designed and explored in terms of the SAR of the substitution at the pendent phenyl ring and the nature of the heterocyclic moieties present in the upper region of the molecule. Selective and potent compounds have been discovered endowed with reduced ClogP with respect to compounds known in the literature. Of particular relevance was the finding that the in vitro affinity of the series was maintained by reducing the overall lipophilicity. The results achieved by this exploration enabled the formulation of a novel hypothesis on the nature of the receptor binding pocket of this class of CRF-1 receptor antagonists, making use of in silico docking studies of the putative nonpeptidic antagonist binding site set up in house by homology modeling techniques.

  DOI：

  10.1021/jm800743q

文献信息

• Dihydropyrrole[2,3-<i>d</i>]pyridine Derivatives as Novel Corticotropin-Releasing Factor-1 Antagonists: Mapping of the Receptor Binding Pocket by in Silico Docking Studies
  作者：Romano Di Fabio、Roberto Arban、Giovanni Bernasconi、Simone Braggio、Frank E. Blaney、Anna M. Capelli、Emiliano Castiglioni、Daniele Donati、Elettra Fazzolari、Emiliangelo Ratti、Aldo Feriani、Stefania Contini、Gabriella Gentile、Damiano Ghirlanda、Fabio M. Sabbatini、Daniele Andreotti、Simone Spada、Carla Marchioro、Angela Worby、Yves St-Denis

  DOI：10.1021/jm800743q

  日期：2008.11.27

  In an effort to discover novel CRF-1 receptor antagonists exhibiting improved physicochemical properties, a dihydropirrole[2,3]pyridine scaffold was designed and explored in terms of the SAR of the substitution at the pendent phenyl ring and the nature of the heterocyclic moieties present in the upper region of the molecule. Selective and potent compounds have been discovered endowed with reduced ClogP with respect to compounds known in the literature. Of particular relevance was the finding that the in vitro affinity of the series was maintained by reducing the overall lipophilicity. The results achieved by this exploration enabled the formulation of a novel hypothesis on the nature of the receptor binding pocket of this class of CRF-1 receptor antagonists, making use of in silico docking studies of the putative nonpeptidic antagonist binding site set up in house by homology modeling techniques.